# An Open Comprative Study of the Prophylactic Efficacy and a Non-comparative Study of the Immunogenicity and Safety of the Inactivated Whole-virion Concentrated Purified Coronavirus Vaccine (CoviVac)

> **NCT05407142** · PHASE3 · UNKNOWN · sponsor: **Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products** · enrollment: 29000 (estimated)

## Conditions studied

- Coronavirus Infections
- Vaccine

## Interventions

- **BIOLOGICAL:** CoviVac vaccine (inactivated whole-virion concentrated purified) manufactured by FSBSI "Chumakov FSC R&D IBP RAS"
- **OTHER:** The data from volunteers from the control group

## Key facts

- **NCT ID:** NCT05407142
- **Lead sponsor:** Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-07-07
- **Primary completion:** 2023-06-01
- **Final completion:** 2023-12-29
- **Target enrollment:** 29000 (ESTIMATED)
- **Last updated:** 2023-02-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05407142

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05407142, "An Open Comprative Study of the Prophylactic Efficacy and a Non-comparative Study of the Immunogenicity and Safety of the Inactivated Whole-virion Concentrated Purified Coronavirus Vaccine (CoviVac)". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT05407142. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*